PT - JOURNAL ARTICLE AU - George Shirreff AU - Jean-Ralph Zahar AU - Simon Cauchemez AU - Laura Temime AU - Lulla Opatowski AU - EMEA-MESuRS working group on the nosocomial modelling of SARS-CoV-2 TI - How well does SARS-CoV-2 spread in hospitals? AID - 10.1101/2021.09.28.21264066 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.28.21264066 4099 - http://medrxiv.org/content/early/2021/09/29/2021.09.28.21264066.short 4100 - http://medrxiv.org/content/early/2021/09/29/2021.09.28.21264066.full AB - Covid-19 poses significant risk of nosocomial transmission, and preventing this requires good estimates of the basic reproduction number R0 in hospitals and care facilities, but these are currently lacking. Such estimates are challenging due to small population sizes in these facilities and inconsistent testing practices.We estimate the patient-to-patient R0 and daily transmission rate of SARS-CoV-2 using data from a closely monitored hospital outbreak in Paris 2020 during the first wave. We use a realistic epidemic model which accounts for progressive stages of infection, stochastic effects and a large proportion of asymptomatic infections. Innovatively, we explicitly include changes in testing capacity over time, as well as the evolving sensitivity of PCR testing at different stages of infection. We conduct rigorous statistical inference using iterative particle filtering to fit the model to the observed patient data and validate this methodology using simulation.We provide estimates for R0 across the entire hospital (2.6) and in individual wards (from 3 to 15), possibly reflecting heterogeneity in contact patterns or control measures. An obligatory mask-wearing policy introduced during the outbreak is likely to have changed the R0, and we estimate values before (8.7) and after (1.3) its introduction, corresponding to a policy efficacy of 85%.Competing Interest StatementLulla Opatowski has received funding from Pfizer for a research project through her institution, outside of the submitted work. Jean-Ralph Zahar has received funding from Pfizer and Merck Sharp and Dohme for a research project through his institution, outside of the submitted work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare that they have no competing interests.Funding StatementThe work was supported directly by internal resources from the French National Institute for Health and Medical Research, the Institut Pasteur, the Conservatoire National des Arts et Métiers, and the University of Versailles-Saint-Quentin-en-Yvelines/University of Paris-Saclay. This study received funding through the MODCOV project from the Fondation de France grant 106059 as part of the alliance framework "Tous unis contre le virus", the Université Paris-Saclay (AAP Covid-19 2020) and the French government through its National Research Agency project SPHINX-17-CE36-0008-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Comité Local d'Ethique pour la Recherche Clinique des HUPSSD Avicenne-Jean Verdier-René Muret has approved the study as protocol CLEA-2021-190. No additional data were collected from patients other than that for clinical use. All patient data were anonymized and only aggregated data are provided in the published work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data analysed for this study at the whole hospital and ward levels are available from the corresponding author upon request. The R scripts used to conduct the analysis are available from the corresponding author upon request. AICAkaike information criterionCIConfidence intervalLTCFLong-term care facilityPCRPolymerase chain reactionPOMPPartially observed Markov processSARSecondary attack rateSARS-CoV-2Severe Acute Respiratory Syndrome coronavirus 2SEIRSusceptible Exposed Infected RecoveredHCWHealthcare worker